Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ABBV-903 Tablet Form 1
ABBV-903 Form 1 · 1 trial · 1 indication
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment
Cmax of ABBV-903
Tmax of ABBV-903
Terminal phase elimination half-life of ABBV-903
AUCt of ABBV-903
AUCinf of ABBV-903
| Arm | Type | Description |
|---|---|---|
| Part 1: Sequence A | EXPERIMENTAL | In Period 1 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. In Period 2 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. Lastly, in Period 3 on Day 1, participants will receive ABBV-903 Tablet Form 1 after a high fat meal. Participants will be followed up for 30 days. |
| Part 1: Sequence B | EXPERIMENTAL | In Period 1 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. In Period 2 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. Lastly, in Period 3 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. Participants will be followed up for 30 days. |
| Part 2: Sequence A | EXPERIMENTAL | In Period 1 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. In Period 2 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. Lastly, in Period 3 on Day 1, participants will receive ABBV-903 Tablet Form 2 after a high fat meal. Participants will be followed up for 30 days. |
| Part 2: Sequence B | EXPERIMENTAL | In Period 1 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. In Period 2 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. Lastly, in Period 3 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. Participants will be followed up for 30 days. |
| Name | Type | Description |
|---|---|---|
| ABBV-903 Tablet Form 1 | DRUG | Oral Tablets |
| ABBV-903 Tablet Form 2 | DRUG | Oral Tablets |
Inclusion Criteria: * BMI is ≥ 18.0 to ≤ 32 kg/m2 after rounding to the tenth. * Negative test result for SARS-CoV-2 infection at screening visit and upon initial confinement. * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, labor...
ABBV-903 Form 1 is an investigational small molecule drug developed by AbbVie Inc. (ticker: ABBV). It is also known as ABBV-903 Tablet Form 1. The specific therapeutic indication has not been disclosed. It is currently in Phase 1 clinical development.
ABBV-903 Form 1 is being developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie is the sponsor of the clinical trial evaluating this drug.
ABBV-903 Form 1 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 trial has been completed.
ABBV-903 Form 1 has been studied in one completed Phase 1 clinical trial, NCT05836506. The trial was titled 'A Study to Assess the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Adult Participants' and enrolled 24 healthy volunteers in the United States.
Yes, ABBV-903 Form 1 is also known as ABBV-903 Tablet Form 1. Both names refer to the same investigational small molecule drug developed by AbbVie Inc.